I agree later stage trials will give better data, however don’t overlook that Cynata added ~$80M in market cap from a month prior to the P1 GvHD interim results vs. after. And this was primarily a result of a single institution (Fidelity) buying on market.
The treatment of diabetic foot ulcers is a significantly larger market than GvHD. In addition, this P1 trial has twice the number of patients (30 vs. 15). I think this makes it more valuable than the P1 GvHD results. I also don’t think the market is applying anything other than a token valuation to this indication based on the current market cap. Add all this together and my opinion is that there is every chance the company gets a similar market cap bump before and after DFU results (assuming they’re good!!)
CYP Price at posting:
31.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)